December 11, 2019
TOKYO, JAPAN - December 11, 2019 - Terumo Corporation (TSE: 4543) today announced that a new osteoporosis medication, Teribone™ 28.2㎍ subcutaneous autoinjector, has launched in the Japanese market for patients with a high risk of fractures. Terumo has signed a development and manufacturing contract with Asahi Kasei Pharma Corporation. The product will be manufactured at Terumo Yamaguchi D&D Corporation, and marketed by Asahi Kasei Pharma.
Asahi Kasei Pharma has been providing lyophilized vial formulation Teribone™ 56.5㎍ subcutaneous injection, since 2011. This new product offers a new treatment option for patients. The product design enables patients to easily self-inject in a home setting.
Teribone™ 28.2㎍ is pre-filled in Terumo's PLAJEX™ silicone oil-free syringe. The highly breakage-resistant polymer material and the low-reactive and stable characteristic of the syringe played a role in the design of this new product, which is safe for self-injection. The product is assembled with a 2-step autoinjector. Patients simply remove the cap and press the device onto the skin to complete the injection. The single dose use medication is also suitable for elderly patients on continual treatment.
Terumo will continue to strive for expansion of their CDMO business to provide new solutions for pharmaceutical companies, and so contribute to better healthcare.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.